alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# FILED

March 20, 1998 Cecil W. Crowson Appellate Court Clerk 

### IN THE COURT OF APPEALS OF TENNESSEE

AT NASHVILLE

JOHN JAY HOOKER, ) ) Plaintiff/Appellant, ) ) VS. ) Davidson Chancery ) No. 96-3601-II SEN. FRED D. THOMPSON, ) ) Defendant/Appellee, ) ) Consolidated and ) Appeal No. ) 01-A-01-9709-CH-00533 JOHN JAY HOOKER, ) ) Plaintiff/Appellant, ) ) Davidson Chancery VS. ) No. 96-2847-III ) DON SUNDQUIST, ET AL., ) ) Defendants/Appellees. )


### ORD ER O N PE TITION TO R EHE AR
The app ellant ha s filed a respectf ul petiti on to rehe ar, which we h ave considered and found to be without merit. It is, therefore, ordered that the petition be and hereby is overruled.

_________________________________ HENRY F. TODD, PRESI DING JUDGE MIDDLE SECTION

_________________________________ BEN H. CANTRELL, JUDGE

_________________________________ WILLIAM C. KOCH, JR., JUDGE
<PAGE>

                                                                    EXHIBIT 31.2

                                  CERTIFICATION

I, Francis H. Murphy, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of Biopure Corporation;

2.    Based on my knowledge, this report does not contain any untrue statement
      of a material fact or omit to state a material fact necessary to make the
      statements made, in light of the circumstances under which such statements
      were made, not misleading with respect to the period covered by this
      report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer(s) and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) for the registrant
      and have:

      (a) Designed such disclosure controls and procedures, or caused such
      disclosure controls and procedures to be designed under our supervision,
      to ensure that material information relating to the registrant, including
      its consolidated subsidiaries, is made known to us by others within those
      entities, particularly during the period in which this report is being
      prepared;

      (b) Evaluated the effectiveness of the registrant's disclosure controls
      and procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of
      the period covered by this report based on such evaluation; and

      (c) Disclosed in this report any change in the registrant's internal
      control over financial reporting that occurred during the registrant's
      most recent fiscal quarter (the registrant's fourth fiscal quarter in the
      case of an annual report) that has materially affected, or is reasonably
      likely to materially affect, the registrant's internal control over
      financial reporting; and

5.    The registrant's other certifying officer(s) and I have disclosed, based
      on our most recent evaluation of internal control over financial
      reporting, to the registrant's auditors and the audit committee of the
      registrant's board of directors (or persons performing the equivalent
      functions):

      (a) All significant deficiencies and material weaknesses in the design or
      operation of internal control over financial reporting which are
      reasonably likely to adversely affect the registrant's ability to record,
      process, summarize and report financial information; and

      (b) Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the registrant's internal control
      over financial reporting.

Date: September 9, 2005

/s/ Francis H, Murphy
-----------------------
Francis H. Murphy
Chief Financial Officer
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.2360 Mycoplasma detection media and components. ( a ) *Identification.* Mycoplasma detection media and components are used to detect and isolate mycoplasma pleuropneumonia-like organisms (PPLO), a common microbial contaminant in cell cultures.
( b ) *Classification.* Class I (general controls). These devices are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60586, Sept. 12, 1980, as amended at 54 FR 25044, June 12, 1989; 66 FR 38789, July 25, 2001]
Exhibit 15.1

LETTER REGARDING UNAUDITED INTERIM FINANCIAL INFORMATION

Board of Directors and Shareholders

STERIS Corporation

We are aware of the incorporation by
reference in the following Registration Statements and related Prospectuses of our report dated August 7, 2009 relating to the unaudited consolidated interim financial statements of STERIS Corporation and subsidiaries that are included in its
Form 10-Q for the quarter ended June 30, 2009:



|                   |  |                                                                                                                      
|------------------ |  | ---------------------------------------------------------------------------------------------------------------------
|RegistrationNumber |  | Description                                                                                                          
|333-65155          |  | Form S-8 Registration Statement  STERIS Corporation 1998 Long-Term Incentive Compensation Plan                      
|                   | 
|333-32005          |  | Form S-8 Registration Statement  STERIS Corporation 1997 Stock Option Plan                                          
|                   | 
|333-06529          |  | Form S-3 Registration Statement  STERIS Corporation                                                                 
|                   | 
|333-01610          |  | Post-effective Amendment to Form S-4 on Form S-8  STERIS Corporation                                                
|                   | 
|33-91444           |  | Form S-8 Registration Statement  STERIS Corporation 1994 Equity Compensation Plan                                   
|                   | 
|33-91442           |  | Form S-8 Registration Statement  STERIS Corporation 1994 Nonemployee Directors Equity Compensation Plan             
|                   | 
|33-55976           |  | Form S-8 Registration Statement  STERIS Corporation 401(k) Plan                                                     
|                   | 
|333-09733          |  | Form S-8 Registration Statement  STERIS Corporation 401(k) Plan                                                     
|                   | 
|333-101308         |  | Form S-8 Registration Statement  STERIS Corporation 2002 Stock Option Plan                                          
|                   | 
|333-91302          |  | Form S-8 Registration Statement  Nonqualified Stock Option Agreement between STERIS Corporation and Mark D. McGinley
|                   | 
|333-137167         |  | Form S-8 Registration Statement  STERIS Corporation Deferred Compensation Plan                                      
|                   | 
|333-136239         |  | Form S-8 Registration Statement  STERIS Corporation 2006 Long-Term Equity Incentive Plan                            

/s/    ERNST & YOUNG
LLP

Cleveland, Ohio

August 7, 2009
In the United States Court of Federal Claims 

OFFICE OF SPECIAL MASTERS

No. 17-198V 

Filed: July 20, 2017

UNPUBLISHED

ALICE ODOM, 

 Petitioner,

v.

SECRETARY OF HEALTH AND 

HUMAN SERVICES,

 Respondent.

Special Processing Unit (SPU); 

Ruling on Entitlement; Concession;

Causation-In-Fact; Influenza (Flu) 

Vaccine; Shoulder Injury Related to 

Vaccine Administration (SIRVA)

Mary Coffey, Coffey & Nichols, LLC, St. Louis, MO, for petitioner.

Ryan Daniel Pyles, U.S. Department of Justice, Washington, DC, for respondent.

RULING ON ENTITLEMENT1

Dorsey, Chief Special Master:

On February 10, 2017, petitioner filed a petition for compensation under the 

National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.,

2 (the 

“Vaccine Act”). Petitioner alleges that she suffered a shoulder injury related to vaccine 

administration (“SIRVA”) following her October 3, 2015 influenza (“flu”) vaccination. 

Petition at 1. The case was assigned to the Special Processing Unit of the Office of 

Special Masters.

On July 19, 2017, respondent filed his Rule 4(c) report in which he concedes that 

petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at 1. 

Specifically, respondent “has concluded that petitioner’s alleged injury is consistent with 

SIRVA; that a preponderance of evidence establishes that her SIRVA was caused-in-

 

1 Because this unpublished ruling contains a reasoned explanation for the action in this case, the 

undersigned intends to post it on the United States Court of Federal Claims' website, in accordance with 

the E-Government Act of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of 

Electronic Government Services). In accordance with Vaccine Rule 18(b), petitioner has 14 days to 

identify and move to redact medical or other information, the disclosure of which would constitute an 

unwarranted invasion of privacy. If, upon review, the undersigned agrees that the identified material fits 

within this definition, the undersigned will redact such material from public access.

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for 

ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 

300aa (2012).
fact by the flu vaccination she received on October 3, 2015; and that no other causes 

for petitioner’s SIRVA were identified.” Id. at 3. Respondent further agrees that the 

statutory six month sequela requirement has been satisfied and that petitioner has 

satisfied all legal prerequisites for compensation under the Vaccine Act. Id.

In view of respondent’s position and the evidence of record, the 

undersigned finds that petitioner is entitled to compensation.

IT IS SO ORDERED.

 s/Nora Beth Dorsey

Nora Beth Dorsey

Chief Special Master
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

# ACTION:

Notice of availability of the ODS Strategic Plan for 2010-2014.

# SUMMARY:

                        The Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH) has completed a strategic planning process resulting in the development of the ODS Strategic Plan for 2010-2014, entitled                         *Strengthening Knowledge and Understanding of Dietary Supplements.*                         The strategic plan is available in pdf format on the ODS Web site:                         *http://ods.od.nih.gov/​pubs/​strategicplan/​StrategicPlan2010-2014.pdf.*

The ODS strategic plan was developed after more than a year's worth of reflection on its programs, activities, and accomplishments, as well as anticipated challenges for the future. It was also shaped by the thoughtful input, comments, and advice received from ODS stakeholder communities throughout the federal government, academia, the dietary supplement industry, consumer advocacy and education groups, and interested consumers.

# FOR FURTHER INFORMATION CONTACT:

                        Office of Dietary Supplements, National Institutes of Health, 6100 Executive Boulevard, Room 3B01, Bethesda, MD 20892-7517, E-mail:                         *ODS@nih.gov.*

# SUPPLEMENTARY INFORMATION:

## Background

The mission of the Office of Dietary Supplements (ODS) is to strengthen knowledge and understanding of dietary supplements by evaluating scientific information, stimulating and supporting research, disseminating research results, and educating the public to foster an enhanced quality of life and health for the U.S. population. ODS was established in the Office of the Director, NIH, in 1995 as a major provision of the Dietary Supplement Health and Education Act of 1994 (DSHEA).

Dated: February 22, 2010.

Paul M. Coates,

Director, Office of Dietary Supplements, Office of the Director, National Institutes of Health.

[FR Doc. 2010-4180 Filed 2-26-10; 8:45 am]

BILLING CODE 4140-01-P
EXHIBIT
      32.1


CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350,


AS
      ADOPTED PURSUANT TO SECTION 906 OF THE


SARBANES-OXLEY ACT OF 2002





In 
      connection  with the quarterly report of Avitar,  Inc. (the 
"Company") on Form10-QSB for the period ending December 31, 2006 as filed with
      the Securities and Exchange  Commission on the date hereof (the 
"Report"),  I, Peter P.  Phildius, Chief Executive Officer of the
      Company certify,  pursuant to 18 U.S.C. Section 1350, as adopted
      pursuant to Section 906 of the  Sarbanes-Oxley Act of 2002, to my
      knowledge,


that:





(1) The Report fully  complies  with the  requirements  of
      Section 13(a) or15(d) of the Securities Exchange Act of 1934; and





(2)  The  information  contained  in the  Report 
fairly  presents,  in all material  respects,  the 
financial  condition  and results of operations of the Company.





Date:
      February 14, 2007





/s/
      Peter
      P. Phildius


---------------------


Peter
      P.
      Phildius Chief


Executive
      Officer
Exhibit 33.7



|     |  |                                                                  
|---- |  | -----------------------------------------------------------------
|LOGO |  | 130 S Jefferson Street
Suite 300 Chicago, IL 60631
(312) 233-6440
|    
|    
|    

REPORT ON ASSESSMENT OF COMPLIANCE WITH APPLICABLE SECURITIES AND

EXCHANGE COMMISSIONS REGULATION AB SERVICING CRITERIA

For
the calendar year ending December 31, 2017, National Tax Search, LLC has been a Tax Service

Vendor for Wells Fargo Bank(the
Servicer).

National Tax Search, LLC (NTS) is responsible for assessing compliance as of December 31, 2017 and for
the period from January 1, 2017 through December 31, 2017 (the Reporting Period) with the servicing criteria set forth in Title 17, Section 229.1122(d) of the Code of Federal Regulations (the CFR). NTS has used
the servicing criteria communicated to NTS by the Servicer to assess compliance with the applicable servicing criteria. Only servicing criteria 1122 (d) (1)(ii), 1122 (d)1(iv), 1122 (d)2(ii), 1122 (d)2(v), 1122(d)2(vi), 1122(d)(4)(xi), and
1122(d)(4)(xii) (the Applicable Servicing Criteria) are applicable to the activities NTS performs with respect to the transactions covered by this report. NTS has determined that the remaining servicing criteria set forth in Item 1122
(d) of the SEC Regulation AB are not applicable to the activities it performs with respect to the transactions covered by this report. The transactions covered by this report include all tax payments made on behalf of the Servicer using NTSs
TaxQ system (the Platform Transactions).

NTS, as a vendor, has assessed its compliance with the Applicable Servicing Criteria for the
Reporting Period and has concluded that NTS has complied, in all material respects, with the Applicable Servicing Criteria as of December 31, 2017 and for the Reporting Period with respect to the Platform Transactions taken as a whole.

Plante & Moran, PLLC, an independent registered public accounting firm, has issued an attestation report on the assessment of compliance with the
Applicable Servicing Criteria as of December 31, 2017 and for the Reporting Period as set forth in this assertion.

National Tax Search, LLC, as
Vendor to Servicer



|                            
|----------------------------
|/s/ Lori D. Eshoo           
|Lori D. Eshoo, President/CEO
|January 26, 2018
<PAGE>

                                                                    EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 In connection with the quarterly report on Form 10-Q of Biopure Corporation for
the period ended January 31, 2005, I, Zafiris G. Zafirelis, Prensident and Chief
Executive Officer, hereby certify, to the best of my knowledge, pursuant to 18
U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

      1.    the Form 10-Q for the period ended January 31, 2005, fully complies
            with the requirements of section 13(a) or 15(d) of the Securities
            Exchange Act of 1934; and

      2.    the information contained in the Form 10-Q for the period ended
            January 31, 2005 fairly presents, in all material respects, the
            financial condition and results of operations of Biopure
            Corporation.

/s/ Zafiris G. Zafirelis
------------------------
Zafiris G. Zafirelis
President and Chief Executive Officer

March 14, 2005
#### § 601.44 Postmarketing safety reporting.

Biological products approved under this program are subject to the postmarketing recordkeeping and safety reporting applicable to all approved biological products.
<PAGE>   1
                                                                    EXHIBIT 11.1

                            A-FEM MEDICAL CORPORATION
                       CALCULATIONS OF NET LOSS PER SHARE


<TABLE>
<CAPTION>
                                            FOR THE THREE MONTHS                     FOR THE NINE MONTHS
                                              ENDED SEPTEMBER 30                          SEPTEMBER 30,
                                      ---------------------------------         ---------------------------------
                                          1999                 1998                 1999                 1998
                                      ------------         ------------         ------------         ------------
<S>                                   <C>                  <C>                  <C>                  <C>
Actual weighted average
   shares outstanding                    9,546,717           12,566,644            9,505,888           13,093,071
Dilutive common stock,
options and warrants using the
   treasury stock method(1)                     --                    -                   --                   --
                                      ------------         ------------         ------------         ------------
Total shares used in per
   share calculations                    9,546,717           12,566,644            9,505,888           13,093,071
                                      ------------         ------------         ------------         ------------
Net loss                              $   (621,672)        $ (1,216,215)        $ (1,971,033)        $ (3,335,707)
                                      ------------         ------------         ------------         ------------
Net loss per share                    $      (0.07)        $      (0.10)        $      (0.21)        $      (0.25)
                                      ============         ============         ============         ============
</TABLE>


---------------------------------

(1) Preferred stock, warrants and options outstanding are not included, as the
    effect would be anti-dilutive.


                                                                          Page 1
Tuesday September 3, 2002

CONCEPTS DIRECT, INC. ANNOUNCES ELECTION OF NEW CHIEF FINANCIAL
OFFICER

Longmont, Colorado, September 3, 2002 -- Concepts Direct, Inc.
(NASDAQ: CDIR) announced the election of Zaid H. Haddad, the
Company's Controller, as Chief Financial Officer, Secretary and
Treasurer.  On September 3, 2002, Cody S. McGarraugh, formerly
Vice President - Finance, Chief Financial Officer, Secretary and
Treasurer of the Company, resigned from the Company to pursue
other interests.

About Concepts Direct, Inc.

Concepts Direct is a direct marketing company focused on building
and managing customer relationships through its catalogs and
internet retailing initiatives. The company sells primarily
personalized paper products and a diverse line of merchandise,
including gift items, home decorative items, collectibles and
apparel. Concepts Direct sells its merchandise primarily via the
Colorful Images, Linda Anderson, SnoopyTM etc., Garfield Stuff,
Linda Anderson's Collectibles, and the Music Stand catalogs. In
addition, the company owns and operates numerous web sites,
including www.ColorfulImages.com, www.LindaAnderson.com,
www.SnoopyStore.com, www.garfieldstuff.com, www.theMusicStand.com
and www.NewBargains.com.

Cautionary Statement

This press release contains certain forward-looking statements as
such term is defined in the Private Securities Litigation Reform
Act of 1995. Company statements that are not historical facts,
including statements about the Company's expectations, beliefs,
plans and objectives are forward-looking statements and involve
various risks and uncertainties, including the risks associated
with starting new businesses. Additional discussion of factors
that could cause actual results to differ materially from
management's expectations, beliefs, plans and objectives is
contained in the Company's SEC filings.

For Further Information Contact

Phillip A. Wiland, Chairman & CEO
Concepts Direct, Inc.
(303) 772-9171
pwiland@conceptsdirectinc.com

Zaid H. Haddad, Chief Financial Officer
Concepts Direct, Inc.
(303) 772-9171
zhaddad@conceptsdirectinc.com